Q3 2025 Glaukos Corp Earnings Call Transcript
Key Points
- Glaukos Corp (GKOS) reported record third-quarter consolidated net sales of $133.5 million, marking a 38% increase on a reported basis compared to the previous year.
- The company raised its full-year 2025 net sales guidance to a range of $490 million to $495 million, up from the previous range of $480 million to $486 million.
- The iDose TR product, a first-of-its-kind intracameral procedural pharmaceutical, generated approximately $40 million in sales during the third quarter, contributing significantly to the company's growth.
- Glaukos Corp (GKOS) announced the FDA approval of Epioxa, a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, which is expected to set a new standard of care.
- The company maintains a strong balance sheet with $278 million in cash and no debt, supporting its ongoing growth and innovation efforts.
- The transition from Photrexa to Epioxa may result in a temporary decline in the corneal health franchise's performance as patients and customers adjust to the new product.
- There are challenges related to payer coverage and reimbursement for Epioxa, which could impact its initial market penetration and sales growth.
- The company faces competitive launch headwinds in several key international markets, which may affect its international glaucoma franchise growth.
- The rollout of Epioxa will require significant investments in patient awareness, education, and detection campaigns, which could strain resources.
- The company anticipates potential headwinds in the fourth quarter due to elevated year-over-year growth comparisons and the transition from Photrexa to Epioxa.
Ladies and gentlemen, thank you for standing by. My name is Colby, and I'll be your conference operator today. At this time, I would like to welcome you to the Glaukos Corporation's third-quarter 2025 financial results conference call. Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at www.glaukos.com. All lines have been placed on mute to prevent any background noise, and after the speakers' remarks, there will be a question-and-answer session. (Operator Instructions) Please note, this call is being recorded and an archived replay will be available online in the investor relations section at www.glaukos.com.
I'll now turn the call over to Chris Lewis, Vice President of Investor Relations and Corporate Affairs.
Thank you, and good afternoon. Joining me today are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
